% | $
Quotes you view appear here for quick access.

Elan Corporation, plc Message Board

bocamp1 213 posts  |  Last Activity: 10 hours ago Member since: Oct 13, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • bocamp1 by bocamp1 Mar 20, 2015 10:43 AM Flag

    Increase volume the past several trading days, increase call activity, and chart breakout says company bought before the 2nd half data even comes out. Company way to cheap.

  • bocamp1 bocamp1 Jan 26, 2015 6:03 PM Flag

    Amount beneficially owned:


    Percent of class


  • bocamp1 bocamp1 Jan 26, 2015 6:05 PM Flag

    They doubled their holdings since last filing. Follow the money

    BLACKROCK FUND ADVISORS 09/30/2014 5,663,201

  • bocamp1 by bocamp1 Feb 24, 2015 12:27 PM Flag

    Big volume there with last tick at .35 for over 8000 contracts ABOVE the offer of 30 cents.........Big leverage bet for much higher price soon. Follow the money

  • bocamp1 bocamp1 Jan 26, 2015 5:47 PM Flag

    11 million shares..........................7%

  • bocamp1 by bocamp1 Apr 10, 2015 11:35 AM Flag

    Over 8000 june 3 1/2 calls just bought at .65 and .7. Going higher

  • bocamp1 by bocamp1 Mar 25, 2015 9:42 PM Flag

    These comments are from an older report which is being updated. Zacks, at no point, questions rgrx's IP protection despite what our knucklehead, message board, crack legal team of Donk and Hollis whine about endlessly. Buy the dips

    RegeneRx holds approximately 150 issued patents and filed patent applications worldwide within 14 patent families.
    These patients cover peptide compositions, uses and formulations related to dermal and ophthalmic indications and
    other organ and tissue repair and regenerative medicine activities, as well as for cosmetic and consumer
    applications with Thymosin beta-4 and its related fragments. These include T 4 patents licensed from the NIH
    issued in the U.S., Europe, and Asia. These patents begin to expire in July 2019. The company has also licensed all
    rights to T 4 applications in respiratory distress syndrome and septic shock from The George Washington
    University (GWU), for which, if commercialized, RegeneRx will pay GWU a 4% royalty on sales in these areas.
    RegeneRx has filed numerous additional U.S. and international patent applications covering various compositions,
    uses, formulations and other components of T 4.

  • bocamp1 bocamp1 Mar 16, 2015 6:26 PM Flag

    Give the guy a break, you expect preformance for his mere 600,000 a year? MA is a disgrace...FUMA
    I expect vaso to go back to its old reporting practices; no CC and report text of earnings after the close on a friday. VASO; one step forward, two steps back..................................
    I hope when this all ends, it wont be just a #$%$ class action suit where shareholders get pennies on the dollar for their troubles, and only the lawyers make out.
    I hope the 3 stooges; Ma, Castle & Leiberman all share a jail cell with 1 toilet for their corrupt activities. Whats you say about that Chairman MA?

  • Reply to

    Bocamp on Rios

    by resellerguy Apr 6, 2015 7:17 PM
    bocamp1 bocamp1 Apr 6, 2015 8:11 PM Flag

    Of course they could have failed. But, proper endpoints run by a professional company might have changed the course of eecp therapy.
    All shareholders would have been all in on a trial. We all were advocates of eecp and invested in eecp. We did not invest in what has now been turned into an Unsuccessful, China based company marketing medical devices with dubious merits............NO demand. They dont even have FDA approval.
    Every biotech company eventually has a binary event with a trial. Its the nature of investing in this area.

  • Wouldnt you know it, the dopey short basher was always a long. And offers advice for buying parameters. Right out of short playbook once again, never admit to having a short position. Donk really a long. Alert the media..........................

    If you believe anything this glue sniffing nutjop says, I got some good Jersey swamp land for sale.

    RGRX going to fill the gap at .48, going back to may of '10.

  • CEO got a raise last year. Why, no one knows, other than compensation committee chairman Castle. And Castle is paid to be on committe, so their is a serious conflict of interest here. Shareholders, until recently, always considered Ma their advocate and gave him the benefit of the doubt. But, making 600k while driving stock price into the ground is unacceptable. If this stock drop continues, its possible Ma's pay package will amount to 10% of market cap. What a friggin thief. Its no wonder he has stopped all communication with shareholders.
    Vaso trades in its own little world. But, this will not continue much longer. The SEC does not allow this type of undeserved overpayment to a CEO. They are slow to react, but Chairman Ma's performance has become so outrageous that even that slow moving government agency will find it within their perview to start asking questions; and Ma HAS NO ANSWERS, as shareholders know............#$%$ MA

  • Reply to


    by guysguysguys2002 Feb 22, 2015 11:10 AM
    bocamp1 bocamp1 Feb 22, 2015 3:28 PM Flag

    You want us to treat Ma with respect? Well, respect is earned not just given, and Ma has earned NOTHING. Especially that 600k pay package. What a disgrace. You post non information that is over 10 years old and has little to do with non eecp Vaso these days.
    Never in my years of investing have I seen a more unresponsive, non transparent, silent management. They have gone completely dark. Silly blog dead, few sec docs(lawsuits, foreign buyouts from employee owned companies where prices are set by China), unanswered e-mails........
    I would be surprized if Ma does a CC this earnings. Maybe Srybnik will wake up out of his stupor and see what Ma and Castle and Leiberman have done to this one time American, EECP company and fire all their worthless butts.

  • Manic: having or relating to a mental illness that causes someone to become very excited or emotional.

  • Reply to

    Major Volume today

    by fl_geezer Mar 25, 2015 4:59 PM
    bocamp1 bocamp1 Mar 25, 2015 5:06 PM Flag

    I dont think you will see much short. I think one of the tweeterhead traders who bought the runnup was getting out. Overall, a good day as stock came back nicely and bidders edge higher towards the close.
    Might see a Zacks update very soon.

  • Restasis is a used to increase the eyes ability to produce tears, which may be deficient in patients with ocular
    inflammation. It effectively masks the symptoms of dry eyes, but does not go after the underlying cause of the
    disease. It s a step-up from OTC dry eye products like Refresh, but does not heal corneal surface defects such as
    ulcerations or neurotrophic keratitis (NK). Despite its limitations, for 2011, Allergan sees Restasis sales between
    $680 and $710 million. We think there is a significant unmet medical need for a product like RGN-259, a potential
    disease modifier, to treat dry eye patients where Restasis fails. At the very least, the RGN-259 my find use in
    combination with Restasis to improve tear production and corneal healing

  • bocamp1 by bocamp1 Mar 30, 2015 5:06 PM Flag

    3 years of declining share price, and today Ma releases a profitable year and no one cares. Do you know why Chairman ma?
    All earninga came from gehc and the market will never afford that a real value because it can end at any time and the products are not vaso's; its just a sales agreement. 3 years since equipment acquistion and we still have nothing to show for it. This is a failure of Ma and 3 years in long enough to make that statement. And judging by the streets reaction, they agree.
    GEHC afforded this company a real lifeline, which Ma has wasted. His cc are still unintelligible. His business plan changes like the weather. No potential investors have any confidence in him, so they stay away.
    Ma and management do not care. They make inflated wages as shareholder value steadily goes down.
    I maintain and say again; Ma is a disgrace and Castle and Leiberman are no better. Fire them all.

  • bocamp1 by bocamp1 Mar 10, 2015 10:45 AM Flag

    Headline Today:
    South Korea's won underperformed regional peers,
    skidding to its weakest in more than 1-1/2 years due to selling
    by offshore funds as the Japanese yen slumped to an
    eight-year low.
    Dollars strength really adds to the attractiveness of an investment in rgrx if your are a Korean or other Asian investor. They have now become familiar with rgrx through g-tree. This is a whole new source of high end investors that the short MM's did not factor into their little rgrx equation. A short blowup is a real possibilty here.
    Lots of news coming along with some new street coverage..............

  • We know you are a lackey for the shorts. And we know you are paid pennies for your posts. Good for you. YOu dont seem to understand that eye indications are covered under the wound healing patents.
    Now, what are your investment recommendations? Do you have any? Something actionable? This is an investment board.

  • bocamp1 by bocamp1 Apr 2, 2015 11:56 AM Flag

    Cant believe those few who know the story here, and have a higher cost basis, are content to sit on their hands and do nothing. No wonder the retail investor never makes any money.
    RGRX is a completely different animal then it was. even from just last year.
    -Trials about to start which can be finished quickly
    -BK off the table and enough cash to see these trials through as expenses are absorbed by China and korean companies. And great JV agreement lets rgrx share in profits.
    -New(updated) coverage any time now.
    -Short trading pattern change
    -New hire close to deals on heart and neuro
    -Deep pocketed Korean company fully committed to rgrx and supported by their government.
    -NO patent concerns. Both companies did full DD on this and are satisfied that wound healing patents cover all eye applications.
    Its a difficult thing to acquire any size in this illiquid stock when news hits. Right now, slow accumulation on the bid taking as much stock as possible without pushing stock much higher. This is a combination of short covering and new "smart" investors.
    A year form now........1+++++++

  • Reply to

    Point of information

    by magdag16 Apr 1, 2015 8:09 AM
    bocamp1 bocamp1 Apr 6, 2015 6:26 PM Flag

    ran into walls that you have no clue about.
    A statement which again points to you being an employee of this dysfunctional company. No one praised Rios, we were all hopeful and believed in Ma at the time. So, huge up front payment and massive backend must have been for a reason? But, was a huge waste of money and the start of the decline in confidence in Ma. This failure was quickly followed by horrible China acquisition and grossly false hype by Ma of the India market. And bailout of Dempsey while no buyback now for real shareholders.
    What is your point reseller. Nothing you say is useful or real as it applies to shareprice today. You defend Rios? Facts are he failed; no one cares why right now.
    And trials were the way to go. Way back when gehc was first done, Ma made a choice to go to his homeland and buy a worthless Chinese company BEFORE their was any demand for those devices/products. Did this guy even take busness 101? What a friggin dope. He should have started a real trial then, 3 years ago. We could have taken all the gehc money from those 3 years and completed trial. We will never know the result, because we have taken a different route. And the result so far, and 3 years is long enough in the business world to say that his way has been a disaster for shareholders. The share price tells the story, not you and your endless false hype.
    Why dont you get a real job with a real company reseller? You work with vaso has been about as productive as Ma's.FUMA